Biophage Pharma Inc.

Biophage is envolving a biosensor using an innovative nanotechnology. These nanosensors are based on impedance spectroscopy-technology that can detect and quantify microbial pathogens in real-time. The unique nanosensors will be built from various proprietary technologies already developed by Biophage (biocapture molecule: phages and antibodies) and by the Biotechnology Research Institute-NRC (signal generation and detection). Biophage has two division - Biosensors division and therapeutic division. The therapeutic division involved in the management of bacterial contaminations which are obvious in medical, veterinary and environmental. The  Biosenzors dedicated to the development and commercialization of novel biosensors; Biophage is envolving a biosensor using an innovative nanotechnology. These nanosensors are based on impedance spectroscopy-technology that can detect and quantify microbial pathogens in real-time. The unique nanosensors will be built from various proprietary technologies already developed by Biophage (biocapture molecule: phages and antibodies) and by the Biotechnology Research Institute-NRC (signal generation and detection). Biophage has two division - Biosensors division and therapeutic division. The therapeutic division involved in the management of bacterial contaminations which are obvious in medical, veterinary and environmental. The Biosenzors dedicated to the development and commercialization of novel biosensors.

Biophage is making up a portfolio of promising new products in the fields of diagnosis and therapy.

The therapeutic division is the development and commercialization of phage-based therapies for:

Management (prevention or significant reduction) of bacterial contamination in the environment, humans or animals.

Management of biological agents potentially involved in terrorism, particularly anthrax.